The combination of the attenuated oncolytic virus talimogene laherparepvec (T-VEC) and the immune checkpoint inhibitor pembrolizumab shows activity and is well-tolerated by advanced melanoma patients.
Mark L. Fuerst
The novel immunotherapy combination of epacadostat plus pembrolizumab shows promising clinical activity in advanced melanoma patients.
A combination of cobimetinib and vemurafenib prolongs overall survival in melanoma patients with BRAF V600 mutations.
A combination of pembrolizumab and low-dose ipilimumab appears to be active and to have a better safety profile than a combination of nivolumab and full-dose ipilimumab in advanced melanoma patients.
Early results from an ongoing trial suggest that pembrolizumab has promising activity in untreated melanoma patients with brain metastases.
Older men are more likely to be diagnosed with multiple primary melanomas and have worse cutaneous malignant melanoma–specific survival than men with a single primary melanoma.
Nivolumab alone or in combination with ipilimumab are promising treatment options for patients with mucosal melanoma, according to a new study.
The checkpoint inhibitors pembrolizumab and nivolumab not only prolong survival in advanced melanoma patients but also maintain health-related quality of life.
The expression of immune markers and T-cell subsets can help predict outcomes of sentinel lymph node–positive melanoma patients, according to a new study.
Advanced melanoma patients successfully treated with a combination of nivolumab and ipilimumab may endure severe side effects, but they do not suffer any clinically meaningful changes in health-related quality of life.